HCA Healthcare (NYSE:HCA) Price Target Raised to $359.00 at Deutsche Bank Aktiengesellschaft

HCA Healthcare (NYSE:HCA) had its price objective boosted by stock analysts at Deutsche Bank Aktiengesellschaft from $330.00 to $359.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 11.21% from the company’s current price.

A number of other research firms have also recently commented on HCA. Barclays began coverage on HCA Healthcare in a research note on Wednesday, March 6th. They issued an “overweight” rating and a $356.00 target price for the company. Royal Bank of Canada lifted their price objective on HCA Healthcare from $308.00 to $322.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $335.00 price objective on shares of HCA Healthcare in a research note on Wednesday. StockNews.com cut HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 15th. Finally, Truist Financial lifted their target price on HCA Healthcare from $320.00 to $345.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $314.05.

HCA Healthcare Trading Down 1.4 %

NYSE HCA opened at $322.82 on Friday. HCA Healthcare has a fifty-two week low of $215.96 and a fifty-two week high of $335.83. The company has a debt-to-equity ratio of 35.07, a quick ratio of 1.02 and a current ratio of 1.18. The stock has a 50 day simple moving average of $319.77 and a two-hundred day simple moving average of $279.40. The stock has a market cap of $85.38 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 1.64 and a beta of 1.65.

HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, January 30th. The company reported $5.90 EPS for the quarter, beating analysts’ consensus estimates of $5.05 by $0.85. The company had revenue of $17.30 billion during the quarter, compared to analysts’ expectations of $16.51 billion. HCA Healthcare had a return on equity of 996.30% and a net margin of 8.07%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the business posted $4.64 EPS. On average, analysts forecast that HCA Healthcare will post 20.49 earnings per share for the current year.

HCA Healthcare announced that its board has initiated a stock buyback plan on Tuesday, January 30th that authorizes the company to buyback $6.00 billion in shares. This buyback authorization authorizes the company to buy up to 7.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at HCA Healthcare

In other news, SVP Sammie S. Mosier sold 1,645 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $312.00, for a total value of $513,240.00. Following the transaction, the senior vice president now directly owns 7,646 shares in the company, valued at $2,385,552. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Michael S. Cuffe sold 3,200 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $306.79, for a total value of $981,728.00. Following the transaction, the executive vice president now directly owns 24,929 shares in the company, valued at $7,647,967.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Sammie S. Mosier sold 1,645 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $312.00, for a total value of $513,240.00. Following the completion of the sale, the senior vice president now owns 7,646 shares in the company, valued at $2,385,552. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,840 shares of company stock valued at $4,588,869. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On HCA Healthcare

Large investors have recently added to or reduced their stakes in the stock. Stone House Investment Management LLC bought a new position in shares of HCA Healthcare during the third quarter valued at approximately $25,000. Northwest Investment Counselors LLC lifted its position in HCA Healthcare by 92.9% during the 3rd quarter. Northwest Investment Counselors LLC now owns 108 shares of the company’s stock worth $27,000 after acquiring an additional 52 shares during the period. BluePath Capital Management LLC acquired a new stake in HCA Healthcare during the 3rd quarter worth about $27,000. Centerpoint Advisors LLC purchased a new position in shares of HCA Healthcare during the 4th quarter valued at about $27,000. Finally, Atlantic Edge Private Wealth Management LLC purchased a new position in shares of HCA Healthcare during the 4th quarter valued at about $27,000. 62.73% of the stock is owned by institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.